 Home > Active Ingredient News > Drugs Articles > Directly hit JPM: Xinda 5-year 20 billion small goal, Zhongsheng hit the global TOP30, Junshi and Baekje have set up Flag...

Directly hit JPM: Xinda 5-year 20 billion small goal, Zhongsheng hit the global TOP30, Junshi and Baekje have set up Flag...

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

solid neon

red cell goats

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Long gone, this offline reunion
.
"Excited", "excited" and "very warm", it is the participation of representatives of domestic biopharmaceutical companies in the 41st J.
P.
Morgan Annual Conference (J.
P.
Morgan.
Morgan Healthcare Conference (JPM).

After the ups and downs of 2022, Chinese biopharmaceutical companies urgently need an opportunity to refresh their spirits and start anew, so that the global biomedical community can have a closer and more comprehensive understanding of Chinese pharmaceutical companies
.

At the meeting, many companies expressed their future development goals, such as Zhongsheng Pharmaceutical, which has comprehensively transformed to innovation, and proposed to become one of the top 30 pharmaceutical companies in the world by 2030; Zai Lab said it expects to be profitable by the end of 2025; Innovent said that the revenue of domestic products is expected to reach 20 billion yuan
in the next five years.
In terms of product research and development progress, Baekje disclosed that its new decade will enter the era of drug discovery, and 10 new molecules will enter the clinic every year in 2024; In terms of BD, Simcere played a new trick and joined hands with the Lecheng Administration to hold the first JPM special promotion conference, attracting more than 140 innovative drug (device) companies from all over the United States and Europe to participate, helping more innovative drugs from all over the world to enter China
through the "Lecheng Plan".

Innovent Biologics: 20 billion in 5 years

Dechao Yu, Founder, Chairman and CEO of Innovent Biopharma Group, said at the JPM conference that Innovent is firmly moving
towards its vision of "growing into a global biopharmaceutical company".

In the more than 10 years since its establishment, Innovent has transformed from an innovative biotechnology company to a leading biopharmaceutical company in China, successfully launched 8 commercial products, and continuously advanced more than 20 product pipelines to different clinical stages
such as new drug market review, critical clinical trial and proof-of-concept.

In 2022, Innovent Biologics has 300 scientists and successfully delivered 6 innovative molecules, becoming a strong innovation driving force
for Innovent Biologics.
Innovent Biologics' global innovation covers multiple new drug forms
such as multi-specific IgG, ISAC, prodrug, antibody fusion cytokines, ADCs, and multi-antibodies.

In terms of international cooperation, Cinda and Eli Lilly deepened cooperation in the field of oncology, and obtained the commercialization rights and priority negotiation rights Chinese mainland three products; Introduction of Tigulixostat, a potentially best-in-class xanthine oxidase inhibitor (XOI) in the late stage of gout from LG Chem; It reached a strategic cooperation with Sanofi to accelerate the development and access of innovative oncology new drugs and obtain an initial strategic equity investment of 300 million euros at Sanofi's premium of 20%, once again creating a new model
of cooperation between local Chinese enterprises and international pharmaceutical companies.

Yu Dechao said that 2023 will be a year
of rapid growth for Innovent Biologics' commercialization pipeline.
Its IBI326 (BCMA-CART), IBI306 (PCSK9) and IBI376 (PI3Kδ) are expected to be available in 2023, with 15-20 products
expected to be available by 2027.
In the next five years, Innovent Biologics' domestic product revenue is expected to reach the target
of 20 billion yuan.
Innovent aims to become a leading biopharmaceutical company in China by 2020-2025 and one of
the world's leading biopharmaceutical companies from 2026 to 2030.

Junshi Biologics: Completed commercialization adjustment

In China, or affected by the news that the new crown oral drug VV116 began to be used in the form of "sympathetic medicine" in 7 hospitals in Shanghai to treat new crown patients, Junshi Biologics rose by more than 8%
in a straight line on the afternoon of January 12.

On the other side of the ocean, Li Ning, CEO of Junshi Biologics, said at the JPM conference that the company has created 6 drug types, 5 treatment types, more than 50 products under research at different stages, and more than 100 clinical studies are underway, covering nearly 10,000 patients
in more than 10 countries and regions around the world.

Junshi Biologics has completed the adjustment of the commercialization team, which has more than 1,100 people, and its product teripulimab has been sold
in more than 4,000 medical institutions and nearly 2,000 professional pharmacies and social pharmacies across the country.

Among the next-generation tumor immunotherapies of Junshi include anti-BTLA monoclonal antibody tifcemalimab (TAB004/JS004), CD112R monoclonal antibody TAB009 (JS009) and TIGIT monoclonal antibody TAB006 (JS006), as well as other potential drug candidates such as CD93 monoclonal antibody JS013 and long-acting IL-21 JS014
。 Among them, tifcemalimab is the first "global new" product of Junshi Biologics, and it is also the world's first anti-tumor anti-BTLA monoclonal antibody
to enter the clinic.

Next, Junshi Biologics will continue to promote the commercialization of "anti-epidemic" drugs and promote the clinical trial
of tifcemalimab in China and the United States.
Planned for 2022- In 2023, 3 new molecular entities were approved for listing
.
In 2024-2025, 5 new molecular solid drugs are expected to be approved for marketing
.
After 2025, more than 10 new molecular entities will be approved for listing
.

BeiGene: Enter the era of drug discovery

"The years 2010 to 2020 were the first prolific decade for BeiGene, and BeiGene has entered a new era
of drug discovery in its second decade after its founding.
" BeiGene co-founder, chairman and CEO Lei Qiang Ou said
.

In the new decade, a number of innovative drugs developed by BeiGene have entered the clinical stage by 2023, including HPK-1 inhibitors, TYK2 allosteric inhibitors, second mitochondrial derived cysteine protease activators (SMAC) mimics, BTK-targeting chimeric degradation activating compounds (CDACs), CEA/4-1BB bispecific antibodies, and more
.

In 2022, BeiGene has had a great
harvest.
Data show that 16 products have been approved for listing in Baekje in 2022, with product revenue exceeding US$1 billion, and product revenue of US$916 million in the first three quarters of 2022, a year-on-year increase of 109%.

Ou Leqiang said at the meeting that at least 4 new molecular entities in the company's pipeline will usher in important progress in 2023; After 2024, it is expected that 10 new molecules will enter the clinic every year, including CDAC, bispecific antibody/trispecific antibody, mRNA therapy, CAR-NK and other cell therapies.
.
.

Legendary Creatures: Turning to Solid Tumors

Founded in 2014, it reached a cooperation with Janssen in 2017, was listed on NASDAQ in 2020, and ushered in the first approved therapy
in 2022.
Legendary creatures with China's first successful "going overseas" CAR-T product brought their own halo
at the JPM conference.

Its BCMA CAR-T therapy cedarchicel has been approved for marketing in the United States, Japan, the European Union and other places for the treatment of multiple myeloma, and at the end of 2022, the new drug application in China was also accepted
.

For this product, Legend Biologics still has a number of clinical studies under investigation, and continues to advance to front-line treatment and even first-line treatment, covering transplantable and transplant-unsuitable patients
.
At the R&D Day event held in October 2022, Legendary Bio revealed that BCMA In line with CAR-T's peak sales target of more than USD 5 billion, Legend Bio and Johnson & Johnson plan to invest USD 250 million to expand the production capacity of the New Jersey plant to a total investment of USD 500 million
.

At the JPM conference, Legend Biologics shared its global clinical development plan for cedarchicel, including a series of clinical programs
for end-line and front-line treatment of multiple myeloma.

For the future pipeline layout, Legend Biologics will continue to promote BCMA CAR-T while developing CAR-T therapy for solid tumors, as well as allogeneic CAR-NK and CAR-NKγδ T cell therapies
.

Hehuang Pharmaceutical: Pipeline priority in the middle and late stages

In the JPM conference report, Hutchison proposed that the next strategic focus is to prioritize late-stage registration studies and the listing of drugs approved by regulatory agencies, especially the global registration of fruquintinib, and will deepen international partnerships to accelerate drug progress
worldwide.
He Huang previously proposed that it is planned for 2023 In the first half of the year, the new drug application submission for fruquintinib was completed, and the new drug application application
was subsequently submitted to the EMA and PMDA.

In fact, Hutchison is actively making a strategic shift to focus on the most cutting-edge drugs in its internal pipeline that are most likely to drive near-term value, with some early-stage research no longer being prioritized for in-house development, and certain other projects considering external business opportunities that allow the company to focus its resources on
its late-stage drugs.

In the first half of last year, Hutchison launched six new clinical trials and continued to expand its own oncology drug commercial team in China, with about 820 employees, covering about 3,000 cancer hospitals and about 30,000 oncologists
.

The three major listed products, fruquintinib, sulfatinib and sevotinib, achieved certain commercial results
in 2022.
As of the first half of 2022, its combined oncology/immunology business revenue was $91.
1 million ($42.
9 million in H1 2021), an increase of 113% year-over-year, with market sales of fruquintinib increasing 26% to $50 million
in the first half of the year.

Next, Hutchison will further enhance and promote the commercialization of its independent innovative drugs, expand production capacity, and accelerate the international layout
of fruquintinib, sevotinib and other products.

Zhongsheng Pharmaceutical: ranked among the top 30 pharmaceutical companies in the world

For Zhongsheng Pharmaceutical, this is the first time that the company's post-90s siblings management has participated in the JPM conference
after the debut of the company's post-90s management in 2022.
At this meeting, Zhongsheng Pharmaceutical shouted the slogan of comprehensive transformation to innovation, and said that by 2030, 40 new drugs under development will be launched, and strive to achieve the goal
of "ranking among the top 30 pharmaceutical companies in the world by 2030".

Previously, at the 2022 mid-year performance exchange meeting of Zhongsheng Pharmaceutical, Xie Qirun, chairman of its board of directors, said that Zhongsheng Pharmaceutical has reached the eve of turning point development, and the next few years will be the harvest year of Zhongsheng Pharmaceutical, and it is expected that by 2023, the entire innovative drug of Zhongsheng Pharmaceutical will reach a milestone scale
of 10 billion yuan.

In the past 10 years, Zhongsheng Pharmaceutical has gradually transformed from a generic drug leader to an innovation-oriented pharmaceutical company
.
In this process, the core strategy of Sinobio Pharmaceutical has gradually focused from the wide net drug development and layout strategy to focusing on the four major advantages of
oncology, surgery/analgesia, liver disease and respiratory.
At the same time, Biopharma is also actively enriching its product pipeline
through cooperation, mergers and acquisitions.
For example, the Chinese commercialization rights of Yiyi Bio's long-acting granulocyte colony-stimulating factor (G-CSF) F-627 were introduced; Introduction of Inventiva's pan-PPAR agonist lanifibranor; Acquisition of Softhale, phion and others
.

In addition, while actively promoting the progress of its self-developed pipeline, Biopharma plans to achieve 10 to 15 blockbuster BD projects in the next three years, and each candidate product has the potential
for peak sales of 1.
5 billion yuan and more than 2 billion yuan.

InnoCare: 13 products in clinical practice

Manish Tandon, Vice President of Business Development, InnoCare delivered a speech
on the progress made in 2022 for important products such as orelabrutinib and the expected milestones in 2023.

InnoCare currently has 13 products in the field of hematological tumors, solid tumors and autoimmune diseases, including BTK inhibitors, anti-CD19 monoclonal antibodies, targeted protein degraders, BCL2 inhibitors, SHP2 allosteric inhibitors, etc
.
6 innovative drugs entered the first clinical phase in 2022
.

The core product of BTK inhibitor orelabrutinib is expected to be approved in China in 2023 for the treatment of relapsed/refractory Waldenstrom macroglobulinemia; and new indications
for patients with relapsed/refractory marginal zone lymphoma.

In 2020, InnoCare was listed on the H-share market, and orelabrutinib was approved in the same year, it took only more than 5 years from project approval to listing, and orelabrutinib contributed 241 million yuan in sales in
2021 without entering the medical insurance catalog.

At the end of 2021, orelabrutinib was included in the national health insurance to benefit more patients
.
As the world's first red-chip biotechnology company to return to A in 2022, in the first three quarters of 2022, InnoCare's total revenue reached 442 million yuan, and the sales revenue of drugs was about 400 million yuan, an increase of 129% over the same period of the previous year, mainly due to the continuous growth of sales after orelabrutinib was included in the national medical insurance, and the R&D investment in the first three quarters reached 475 million yuan
.
Cash and cash equivalents increased by 37.
5%
year-on-year to RMB9.
23 billion in the first three quarters.

In 2023, tafasitamab, the anti-CD19 antibody, plans to complete a key registration study for relapsed/refractory DLBCL in Chinese mainland and apply for marketing
to the NMPA.
At the end of 2022, the drug combined with lenalidomide was approved for marketing in Hong Kong, China, in addition to accelerating the implementation of the drug in various places Huimin Bao, and has been included in the overseas special drug list
of 18 local commercial insurance in many provinces and cities.

Simcere Pharmaceutical: BD's new model

As a long-established pharmaceutical company, Simcere Pharmaceutical's resolute innovation and transformation is often talked about
in the industry.
In addition to the R&D strategy of "focusing on more effective and insisting on differentiation", its strategy on BD is also remarkable
.

Unlike other companies that focus on showcasing their products and strategies, Simcere Pharmaceutical and Lecheng Administration held a special JPM promotion conference in the United States to promote more innovative drugs from all over the world to enter China
through the "Lecheng Solution".
It is understood that this conference is the first special promotion conference held in the United States in the Lecheng Pilot Zone, and it is also one of a series of
measures for the Lecheng Pilot Zone to carry out strategic cooperation and collaborative innovation with Simcere Pharmaceutical.

The conference attracted more than 140 innovative drug (device) companies from all over the United States and Europe, including CTI BioPharma, Agios, Marinus, Phathom and more than 10 listed pharmaceutical companies
.

Lecheng Pilot Zone is one of the key parks of Hainan Free Trade Port, and also a pilot area for China's medical and pharmaceutical reform and innovation development, which has introduced a total of 282 kinds of international innovative drugs and devices, becoming the main channel
for international innovative drugs and devices to enter the Chinese mainland.
Up to now, 9 international innovative pharmaceutical and device products have been approved for marketing
in China by using Lecheng real-world data to assist clinical evaluation.
Among them, Simcere Pharmaceutical and G1 Therapeutics' co-developed world's first pre-chemotherapy full-line bone marrow protection innovative drug Cosella (triracillide hydrochloride for injection) was successfully approved for marketing in China in July 2022, only one year and five months after the drug was approved in the United States, creating "Simcere Speed", and also refreshing the "Lecheng Speed
" through the close collaborative innovation of Simcere Pharmaceutical and Lecheng.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.